XPH:NYE-SPDR® S&P Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 44.4

Change

+0.04 (+0.09)%

Market Cap

N/A

Volume

8.59K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-01 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.81 (-0.53%)

USD 41.71B
FHLC Fidelity® MSCI Health Care In..

-0.46 (-0.63%)

USD 2.97B
FXH First Trust Health Care AlphaD..

-1.05 (-0.94%)

USD 1.29B
PPH VanEck Pharmaceutical ETF

-0.49 (-0.52%)

USD 0.72B
XHE SPDR® S&P Health Care Equipme..

-2.02 (-2.23%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.15 (-0.63%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

+0.19 (+0.51%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

-1.90 (-1.96%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.39 (-1.32%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-0.71 (-1.13%)

USD 0.02B

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.68% 23% F 47% F
Dividend Return 1.26% 88% B+ 25% F
Total Return 7.94% 41% F 41% F
Trailing 12 Months  
Capital Gain 15.03% 9% A- 45% F
Dividend Return 1.81% 89% A- 25% F
Total Return 16.83% 18% F 40% F
Trailing 5 Years  
Capital Gain 25.74% 23% F 59% D-
Dividend Return 4.94% 63% D 14% F
Total Return 30.69% 32% F 51% F
Average Annual (5 Year Horizon)  
Capital Gain 0.14% N/A N/A 37% F
Dividend Return 0.84% N/A N/A 29% F
Total Return 0.69% N/A N/A 17% F
Risk Return Profile  
Volatility (Standard Deviation) 15.30% N/A N/A 63% D
Risk Adjusted Return 5.47% N/A N/A 28% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike